MCID: TRP002
MIFTS: 49

Tropical Spastic Paraparesis

Categories: Infectious diseases, Neuronal diseases

Aliases & Classifications for Tropical Spastic Paraparesis

MalaCards integrated aliases for Tropical Spastic Paraparesis:

Name: Tropical Spastic Paraparesis 12 75 54 15 17 72
Tropical Spastic Paraplegia 12 33
Paraparesis, Tropical Spastic 44
Paraparesis Tropical Spastic 55
Htlv-Associated Myelopathy 12
Tropical Spastic Paralysis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:321
MeSH 44 D015493
SNOMED-CT 68 45129002
ICD10 33 G04.1
UMLS 72 C0030481

Summaries for Tropical Spastic Paraparesis

NINDS : 54 For several decades the term “tropical spastic paraparesis” (TSP) has been used to describe a chronic and progressive disease of the nervous system that affects adults living in equatorial areas of the world and causes progressive weakness, stiff muscles, muscle spasms, sensory disturbance, and sphincter dysfunction. The cause of TSP was obscure until the mid-1980s, when an important association was established between the human retrovirus — human T-cell lymphotrophic virus type 1 (also known as HTLV-1) — and TSP. TSP is now called HTLV-1 associated myelopathy/ tropical spastic paraparesis or HAM/TSP. The HTLV-1 retrovirus is thought to cause at least 80 percent of the cases of HAM/TSP by impairing the immune system. In addition to neurological symptoms of weakness and muscle stiffness or spasms, in rare cases individuals with HAM/TSP also exhibit uveitis (inflammation of the uveal tract of the eye), arthritis (inflammation of one or more joints), pulmonary lymphocytic alveolitis (inflammation of the lung), polymyositis (an inflammatory muscle disease), keratoconjunctivitis sicca (persistent dryness of the cornea and conjunctiva), and infectious dermatitis (inflammation of the skin). The other serious complication of HTLV-1 infection is the development of adult T-cell leukemia or lymphoma. Nervous system and blood-related complications occur only in a very small proportion of infected individuals, while most remain largely without symptoms throughout their lives. The HTLV-1 virus is transmitted person-to-person via infected cells: breast-feeding by mothers who are seropositive (in other words, have high levels of virus antibodies in their blood), sharing infected needles during intravenous drug use, or having sexual relations with a seropositive partner. Less than 2 percent of HTLV-1 seropositive carriers will become HAM/TSP patients.

MalaCards based summary : Tropical Spastic Paraparesis, also known as tropical spastic paraplegia, is related to htlv-1 associated myelopathy/tropical spastic paraparesis and adult t-cell leukemia. An important gene associated with Tropical Spastic Paraparesis is CNTN2 (Contactin 2), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Pentoxifylline and Zidovudine have been mentioned in the context of this disorder. Affiliated tissues include t cells, spinal cord and breast, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A viral infectious disease that results in inflammation located in spinal cord, has material basis in Human T-lymphotropic virus 1, which is transmitted by sexual contact, and transmitted by breast feeding. The infection has symptom spastic weakness of both legs, has symptom muscle stiffness, has symptom sensory disturbance, and has symptom spasms.

Wikipedia : 75 Tropical spastic paraparesis (TSP), is a medical condition that causes weakness, muscle spasms, and... more...

Related Diseases for Tropical Spastic Paraparesis

Diseases related to Tropical Spastic Paraparesis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 300)
# Related Disease Score Top Affiliating Genes
1 htlv-1 associated myelopathy/tropical spastic paraparesis 35.5 IL2 IFNL3
2 adult t-cell leukemia 31.5 IL2RA IL2 FOXP3 CNTN2
3 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.0 IL10 IFNG FOXP3
4 t-cell leukemia 30.9 NFKB1 IL2RA IL2 CNTN2
5 measles 30.9 IL6 IL2 IFNG
6 mumps 30.8 IL2RA IL2 IFNG
7 schistosomiasis 30.7 IL2 IL10 IFNG
8 uveitis 30.7 IL2RA IL10 IFNG CXCR3
9 alopecia areata 30.6 IL2RA IL2 IFNG
10 prostatitis 30.6 IL6 IL2 IL10
11 toxoplasmosis 30.6 IL6 IL10 IFNG
12 cutaneous t cell lymphoma 30.6 IL2RA IL2 IFNG
13 folliculitis 30.5 IL2RA IFNG CCL5
14 acquired immunodeficiency syndrome 30.3 IL6 IL2RA IL2 IL10 IFNG
15 graft-versus-host disease 30.3 IL6 IL2 IL10 IFNG
16 mycosis fungoides 30.2 IL2RA IL2 CXCR3
17 central nervous system disease 30.2 MMP9 IL6 IFNG CXCR3
18 human t-cell leukemia virus type 2 30.1 NFKB1 IFNG CNTN2
19 nervous system disease 29.9 MMP9 IL6 IL10 IFNG CXCR3
20 autoimmune disease 29.8 IL6 IL2RA IL2 IL10 IFNG FOXP3
21 lung disease 29.3 MMP9 IL6 IL10 CXCR3 CCL5
22 human immunodeficiency virus type 1 28.9 NFKB1 IL6 IL2 IL10 IFNG CCL5
23 systemic lupus erythematosus 28.2 IL6 IL2RA IL2 IL10 IFNG FOXP3
24 multiple sclerosis 28.1 MMP9 IL6 IL2RA IL2 IL10 IFNG
25 myelopathy, htlv-1-associated 12.7
26 retrovirus-associated myelopathy 12.0
27 human t-cell leukemia virus type 1 11.9
28 spastic paraparesis 11.4
29 leukemia, t-cell, chronic 11.0
30 spasticity 10.7
31 cephalosporin allergy 10.7 IL10 IFNG
32 variola major 10.6 IL2 IFNG
33 acute necrotizing encephalitis 10.6 IFNG FOXP3
34 fixed drug eruption 10.6 IL2 IFNG
35 autoimmune atherosclerosis 10.6 IL10 FOXP3
36 sporotrichosis 10.6 IL10 IFNG
37 t-cell adult acute lymphocytic leukemia 10.6
38 autoimmune myocarditis 10.5 IL6 IFNG
39 dermatitis 10.5
40 nickel allergic contact dermatitis 10.5 IL10 IFNG
41 clonorchiasis 10.5 IL2 IL10 IFNG
42 eye lymphoma 10.5 IL6 IL10
43 chronic active epstein-barr virus infection 10.5 IL2 IL10 IFNG
44 berylliosis 10.5 IL2 IFNG
45 coccidiosis 10.5 IL2 IL10 IFNG
46 syphilis 10.5
47 leprosy 3 10.5 IL2 IL10 IFNG
48 lepromatous leprosy 10.5 IL2 IL10 IFNG
49 testicular disease 10.5 IL2 IL10 IFNG
50 autoimmune uveitis 10.5 IL2 IL10 IFNG

Graphical network of the top 20 diseases related to Tropical Spastic Paraparesis:



Diseases related to Tropical Spastic Paraparesis

Symptoms & Phenotypes for Tropical Spastic Paraparesis

MGI Mouse Phenotypes related to Tropical Spastic Paraparesis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.11 CCL5 CXCR3 FOXP3 IFNG IFNL3 IL10
2 immune system MP:0005387 10.06 CCL5 CXCR3 FOXP3 IFNG IFNL3 IL10
3 digestive/alimentary MP:0005381 10.01 FOXP3 IFNG IL10 IL2 IL2RA IL6
4 liver/biliary system MP:0005370 9.73 FOXP3 IFNG IL10 IL2 IL6 NFKB1
5 neoplasm MP:0002006 9.63 CXCR3 IFNG IL10 IL2 IL6 MMP9
6 respiratory system MP:0005388 9.61 CXCR3 FOXP3 IFNG IL10 IL2 IL2RA
7 vision/eye MP:0005391 9.17 FOXP3 IFNG IL10 IL2 IL2RA IL6

Drugs & Therapeutics for Tropical Spastic Paraparesis

Drugs for Tropical Spastic Paraparesis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 47)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
2
Zidovudine Approved Phase 2, Phase 3 30516-87-1 35370
3
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
4
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
5
Mogamulizumab Approved, Investigational Phase 3 1159266-37-1
6 Free Radical Scavengers Phase 3
7 Antioxidants Phase 3
8 Phosphodiesterase Inhibitors Phase 3
9 Protective Agents Phase 3
10 Radiation-Protective Agents Phase 3
11 Platelet Aggregation Inhibitors Phase 3
12 Vasodilator Agents Phase 3
13 Anti-Infective Agents Phase 2, Phase 3
14 Nucleic Acid Synthesis Inhibitors Phase 2, Phase 3
15 Reverse Transcriptase Inhibitors Phase 2, Phase 3
16 Anti-HIV Agents Phase 2, Phase 3
17 Antiviral Agents Phase 2, Phase 3
18 Anti-Retroviral Agents Phase 2, Phase 3
19 Antimetabolites Phase 2, Phase 3
20 Dermatologic Agents Phase 2, Phase 3
21 Antirheumatic Agents Phase 2, Phase 3
22 Immunologic Factors Phase 2, Phase 3
23 Antifungal Agents Phase 2, Phase 3
24 Cyclosporins Phase 2, Phase 3
25 Immunosuppressive Agents Phase 2, Phase 3
26 Calcineurin Inhibitors Phase 2, Phase 3
27
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
28
Infliximab Approved Phase 2 170277-31-3
29 Adjuvants, Immunologic Phase 2
30 Interferon-beta Phase 2
31 interferons Phase 2
32 Janus Kinase Inhibitors Phase 2
33 Gastrointestinal Agents Phase 2
34 Antibodies Phase 1
35 Antibodies, Monoclonal Phase 1
36 Immunoglobulins Phase 1
37
Valproic acid Approved, Investigational 99-66-1 3121
38 Raltegravir Potassium Early Phase 1
39 Integrase Inhibitors Early Phase 1
40 HIV Integrase Inhibitors Early Phase 1
41 Neurotransmitter Agents
42 Tranquilizing Agents
43 Central Nervous System Depressants
44 GABA Agents
45 Psychotropic Drugs
46 Antimanic Agents
47 Anticonvulsants

Interventional clinical trials:

(show all 25)
# Name Status NCT ID Phase Drugs
1 HTLV Blot 2.4 Post-Market Clinical Study of Neurological Disorders and HTLV Positive Specimens Completed NCT03226119 Phase 4
2 Open-Label, Exploratory Study of the Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) Unknown status NCT01343355 Phase 2, Phase 3 Tamibarotene
3 Effectiveness of Pentoxifylline in Attenuating Neurological Disease Associated With HTLV-1 and Negative Modulator of Pathological Immune Response. Completed NCT01472263 Phase 3 Pentoxifylline;Placebo
4 Study Of Valproic Acid To Treat TSP/HAM Patients In Sao Paulo, Brazil Completed NCT00681980 Phase 3 Valproic acid;costicosteroids;valproid acid plus corticosteroids
5 Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial Completed NCT00272480 Phase 2, Phase 3 Zidovudine/lamivudine;Placebos
6 The HAM Ciclosporin Study : an Observational Trial of Therapy in Early or Progressing HAM/TSP Completed NCT00773292 Phase 2, Phase 3 ciclosporin
7 A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0761 in Patients With HTLV-1 Associated Myelopathy (HAM) Active, not recruiting NCT03191526 Phase 3 KW-0761 0.3 mg/kg IV;Placebo (saline)
8 Combined Virological and Immunological Evaluation of Treatment of Patients With Early HTLV-1-Associated Myelopathy With Recombinant Human Interferon Beta-1a Completed NCT00001785 Phase 2 Recombinant human interferon beta-1a
9 Phase II Trial Evaluating the Safety and Efficacy of Ruxolitinib in Patients With Smoldering and Chronic Adult T-cell Leukemia (ATL) Recruiting NCT01712659 Phase 2 Ruxolitinib;ruxolitinib
10 An Open, Non-randomised Pilot Study of Anti-TNF-alpha Therapy in Early or Progressing HAM/TSP Terminated NCT00823641 Phase 2 Infliximab
11 Phase I Study of HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Using the Humanized MiK-Beta-1 Monoclonal Antibody Directed Toward the IL-2L-15R-Beta; Subunit (CD122) That Blocks IL-15 Action Completed NCT00076843 Phase 1 Hu MiK-Beta-1
12 Evaluation of the MP Diagnostics HTLV Blot 2.4 Unknown status NCT01467024
13 Effect of Raltegravir in Patients With Myelopathy/Tropical Spastic Paraparesis Associated With Infection by Human T-Lymphotropic Virus 1 (HTLV-1). Pilot Study Completed NCT02655471 Early Phase 1 "Raltegravir" and "Zidovudine"
14 A Study of Familial and Genetic Aspects of Adult T-Cell Leukemia/Lymphoma, Tropical Spastic Paraparesis and Infective Dermatitis in Jamaica Completed NCT00340821
15 Effects of Physiotherapy in the Treatment of Neurogenic Bladder in Patients Infected With Human T-Lymphotropic Virus 1 Completed NCT01651819
16 MRI Investigation Of The CNS In HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Completed NCT00034723
17 Combined Clinical, Immunological and Virological Assessment of Patients With Multiple Sclerosis (MS) Completed NCT00001156
18 Evaluation of the MP Diagnostics HTLV Blot 2.4 Completed NCT03146013
19 Influence of IL28B Genetic Variation on the Phenotype Infection of HTLV-1 Completed NCT01754311
20 Pilot Study of Raltegravir, an Integrase Inhibitor, in Human T-Cell Lymphotrophic Virus-1(HTLV-1) Associated Myelopathy, Tropical Spastic Paraparesis (HAM/TSP) Completed NCT01867320 Early Phase 1 Raltegravir
21 NIB Repository Protocol Completed NCT01581567
22 Retrovirus Epidemiology Donor Study I (REDS I) Completed NCT00005278
23 Immuno-Virological Evaluation of Human T Cell Lymphotropic Virus Infection and Associated Neurological Diseases Recruiting NCT00001778
24 Electromiography Study in the Respiratory Muscle Training in Human Lymphotropic Virus Type 1 Recruiting NCT03829709
25 Open Label Study of the Clinical and Laboratory Effects of Valproic Acid In HAM/TSP Terminated NCT00519181 Valproic Acid

Search NIH Clinical Center for Tropical Spastic Paraparesis

Cochrane evidence based reviews: paraparesis, tropical spastic

Genetic Tests for Tropical Spastic Paraparesis

Anatomical Context for Tropical Spastic Paraparesis

MalaCards organs/tissues related to Tropical Spastic Paraparesis:

41
T Cells, Spinal Cord, Breast, Lung, Skin, Eye, Brain

Publications for Tropical Spastic Paraparesis

Articles related to Tropical Spastic Paraparesis:

(show top 50) (show all 1517)
# Title Authors PMID Year
1
Reduced Foxp3 expression with increased cytomegalovirus-specific CTL in HTLV-I-associated myelopathy. 9 38
18639344 2008
2
High production of RANTES and MIP-1alpha in the tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM). 9 38
17588676 2007
3
Blockade of IL-2 receptor suppresses HTLV-I and IFN-gamma expression in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. 9 38
17409595 2007
4
Levels of serum chemokines discriminate clinical myelopathy associated with human T lymphotropic virus type 1 (HTLV-1)/tropical spastic paraparesis (HAM/TSP) disease from HTLV-1 carrier state. 9 38
16879249 2006
5
Foxp3 represses retroviral transcription by targeting both NF-kappaB and CREB pathways. 9 38
16652169 2006
6
Preclinical and phase I clinical trial of blockade of IL-15 using Mikbeta1 monoclonal antibody in T cell large granular lymphocyte leukemia. 9 38
16387851 2006
7
Involvement of p38 MAPK signaling pathway in IFN-gamma and HTLV-I expression in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. 9 38
15652420 2005
8
Longer dinucleotide repeat polymorphism in matrix metalloproteinase-9 (MMP-9) gene promoter which correlates with higher HTLV-I Tax mediated transcriptional activity influences the risk of HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP). 9 38
15465610 2004
9
TIMPs and MMPs expression in CSF from patients with TSP/HAM. 9 38
12697269 2003
10
Detection of myelin basic protein in cerebrospinal fluid and serum from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. 9 38
12564844 2002
11
Detection of myelin basic protein in cerebrospinal fluid. 9 38
12465458 2002
12
High frequencies of Th1-type CD4(+) T cells specific to HTLV-1 Env and Tax proteins in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. 9 38
11964301 2002
13
Up-regulation of interleukin-12 receptor expression in peripheral blood mononuclear cells of patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. 9 38
11959151 2002
14
IRF-4 activities in HTLV-I-induced T cell leukemogenesis. 9 38
11846984 2002
15
IL-15 plays a major role in the persistence of Tax-specific CD8 cells in HAM/TSP patients. 9 38
11717409 2001
16
How does interleukin 15 contribute to the pathogenesis of HTLV type 1-associated myelopathy/tropical spastic paraparesis? 9 38
11080816 2000
17
[Increased activity of metalloproteinases and their inhibitors in cerebrospinal fluid of patients with tropical spastic paraparesis]. 9 38
11016056 2000
18
Involvement of IL-15 in the pathogenesis of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: implications for therapy with a monoclonal antibody directed to the IL-2/15R beta receptor. 9 38
10491011 1999
19
Increased levels of soluble Fas ligand in CSF of rapidly progressive HTLV-1-associated myelopathy/tropical spastic paraparesis patients. 9 38
10430056 1999
20
HTLV-I-infected T cells evade the antiproliferative action of IFN-beta. 9 38
10329542 1999
21
Gelatinase activity of matrix metalloproteinases in the cerebrospinal fluid of various patient populations. 9 38
10604277 1999
22
Predominant expression of Fas ligand mRNA in CD8+ T lymphocytes in patients with HTLV-1 associated myelopathy. 9 38
9817448 1998
23
Matrix metalloproteinase 9 (gelatinase B) in cerebrospinal fluid of HTLV-1 infected patients with tropical spastic paraparesis. 9 38
9633766 1998
24
Human T cell lymphotropic virus type I Tax protein trans-activates interleukin 15 gene transcription through an NF-kappaB site. 9 38
9482906 1998
25
Costimulation of cytokine gene expression in T cells by the human T leukemia/lymphotropic virus type 1 trans activator Tax. 9 38
8648737 1996
26
Sequence analysis of human T cell lymphotropic virus type I (HTLV-I) Env genes amplified from central nervous system tissues of patients with HTLV-I-associated myelopathy or leukemia. 9 38
8778566 1995
27
Cytokine expression in the spinal cord lesions in HTLV-I-associated myelopathy. 9 38
8301322 1994
28
Virion-associated trans-regulatory protein of human T-cell leukemia virus type I. 9 38
1540409 1992
29
Failure to demonstrate human T cell lymphotropic virus type I in multiple sclerosis patients. 9 38
2189023 1990
30
Conflicting effects of poly(ADP-ribose) polymerase inhibitor on cell-mediated and virion-mediated HTLV-1 infection. 38
31299194 2019
31
Curcumin increased the expression of c-FLIP in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients. 38
31074052 2019
32
Hodgkin-like adult T-cell leukemia/lymphoma that developed during the follow-up of HTLV-1 associated myelopathy/tropical spastic paraparesis. 38
31391405 2019
33
Comparative virology of HTLV-1 and HTLV-2. 38
31391116 2019
34
Human T-Cell Lymphotropic Virus Type 1 and associated diseases in Latin America. 38
31183938 2019
35
Balance Impairments in Patients with Human T-Cell Lymphotropic Virus Type 1 Infection. 38
31391511 2019
36
Clinical trial of a humanized anti-IL-2/IL-15 receptor β chain in HAM/TSP. 38
31402625 2019
37
Current approaches for detection of human T-lymphotropic virus Type 1: A systematic review. 38
30633358 2019
38
Pentosan Polysulfate Demonstrates Anti-human T-Cell Leukemia Virus Type 1 Activities In Vitro and In Vivo. 38
31167921 2019
39
Memory impairment: an intermediate clinical syndrome symptom in HTLV-1-infected patients? 38
31314846 2019
40
Phenotypic and functional changes in gamma delta T lymphocytes from HTLV-1 carriers. 38
31287591 2019
41
Prevalence of human T-cell lymphotropic virus and the socio-demographic and risk factors associated with the infection among post-natal clinics women in Zaria, Nigeria. 38
31339431 2019
42
Low Frequency Of Regulatory B-Cells And Increased CD4+ and CD8+ Interferon-γ-producing cells in patients with tropical spastic paraparesis associated with human T-cell lymphotropic virus type. 38
31340370 2019
43
Repurposing multiple sclerosis drugs: a review of studies in neurological and psychiatric conditions. 38
31100209 2019
44
Essential Role of HTLV-1 orf-I in Lethal Proliferation of CD4+ Cells in Humanized Mice. 38
31315992 2019
45
HTLV-1-infected asymptomatic carriers compared to HAM/TSP patients over-express the apoptosis- and cytotoxicity-related molecules. 38
31317252 2019
46
Delimitation of the upstream region of NFKBIA gene associated with HTLV-1-associated myelopathy/tropical spastic paraparesis using candidate Tag-SNPs in Peruvian HTLV-1 infected individuals. 38
31226330 2019
47
Human T-cell lymphotropic virus 1/2 and human immunodeficiency virus antibodies identification among transactional sex workers and drug users in the Dominican Republic. 38
30892643 2019
48
Functional capacity of natural killer cells in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients. 38
31101076 2019
49
Thioredoxin reductase gene expression and activity among human T-cell lymphotropic virus type 1-infected patients. 38
30489643 2019
50
Pain and Quality of Life in Human T-cell Lymphotropic Virus Type 1-Associated Myelopathy or Tropical Spastic Paraparesis After Home-Based Exercise Protocol: A Randomized Clinical Trial. 38
31038621 2019

Variations for Tropical Spastic Paraparesis

Expression for Tropical Spastic Paraparesis

Search GEO for disease gene expression data for Tropical Spastic Paraparesis.

Pathways for Tropical Spastic Paraparesis

Pathways related to Tropical Spastic Paraparesis according to GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.93 NFKB1 NCR3 MMP9 KLRK1 KIR2DL3 IL6
2
Show member pathways
13.64 NFKB1 IL6 IL2RA IL2 IL10 IFNL3
3
Show member pathways
13.52 NFKB1 IL6 IL2RA IL2 IL10 IFNG
4
Show member pathways
13.4 NFKB1 IL6 IL2RA IL2 IL10 CXCR3
5
Show member pathways
13.29 NFKB1 IL6 IL2RA IL2 IL10 CXCR3
6
Show member pathways
13.26 NFKB1 MMP9 IL6 IL2RA IL2 IL10
7
Show member pathways
13.09 NFKB1 IL6 IL2 IL10 IFNG CCL5
8 12.82 NFKB1 MMP9 IL6 IL2RA IL2 IFNG
9
Show member pathways
12.78 NFKB1 KIR2DL3 IL6 IL2RA IL2 IL10
10
Show member pathways
12.77 NFKB1 IL6 IFNL3 IFNG CCL5
11
Show member pathways
12.64 NFKB1 IL2RA IL2 IL10 IFNG
12
Show member pathways
12.59 NFKB1 IL6 IL2 IL10 IFNG
13
Show member pathways
12.55 NFKB1 IL6 IL2 IL10 IFNG
14
Show member pathways
12.51 NCR3 KLRK1 KIR2DL3 IL2 IFNG
15
Show member pathways
12.49 NFKB1 IL6 IL2RA IL2 IL10 IFNG
16 12.43 NFKB1 IL2RA IL2 IL10 IFNG FOXP3
17
Show member pathways
12.37 IL6 IL2RA IL2 IL10 IFNL3 IFNG
18 12.36 NFKB1 IL6 IL2RA IL2
19
Show member pathways
12.35 NFKB1 MMP9 IL6 IFNG
20
Show member pathways
12.32 NFKB1 IL6 IL2 IFNG CCL5
21
Show member pathways
12.27 IL6 IL2RA IL2 IL10 IFNG
22 12.25 NFKB1 IL6 IL10 IFNG
23
Show member pathways
12.23 NFKB1 IL6 IL2 IL10
24 12.2 NFKB1 MMP9 IL6 IFNG
25 12.07 NFKB1 MMP9 IFNG
26
Show member pathways
12.07 IL6 IL2 IL10 IFNG
27 12.05 NCR3 KLRK1 KIR2DL3
28
Show member pathways
12.05 IL2RA IL2 IFNG
29
Show member pathways
12.04 IL6 IL2RA IL2 IL10 IFNG CCL5
30 12.03 MMP9 IL6 IL2 IFNG
31
Show member pathways
12.02 MMP9 IL6 IFNG
32
Show member pathways
12.01 NFKB1 IL2RA IL2
33
Show member pathways
11.99 NFKB1 IL2RA IL2 IFNG
34 11.98 NFKB1 MMP9 IL6 CCL5
35 11.97 MMP9 IL6 IL10
36 11.95 NFKB1 IL6 IFNG
37
Show member pathways
11.94 NFKB1 IL2RA IL2
38 11.91 NFKB1 IL6 IL10 IFNG
39
Show member pathways
11.88 NFKB1 IL6 FOXP3
40 11.87 IL6 IFNG CCL5
41 11.85 IL6 IL2RA IL2 IL10 IFNG
42 11.82 NFKB1 IL6 IFNG
43 11.81 NFKB1 IL6 IL2 IFNG
44 11.78 NFKB1 IL6 IL10
45
Show member pathways
11.77 IL2RA IL2 IFNG FOXP3
46 11.75 IL6 IL2 IL10 IFNG
47 11.71 NFKB1 IL2 IFNG
48 11.7 NFKB1 MMP9 IL6
49 11.69 MMP9 IL6 CCL5
50
Show member pathways
11.69 NFKB1 IL2RA IL2 FOXP3

GO Terms for Tropical Spastic Paraparesis

Cellular components related to Tropical Spastic Paraparesis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 MMP9 IL6 IL2 IL10 IFNL3 IFNG
2 extracellular region GO:0005576 9.23 NFKB1 MMP9 IL6 IL2 IL10 IFNL3

Biological processes related to Tropical Spastic Paraparesis according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.93 NFKB1 MMP9 IL6 IL2 IL10
2 inflammatory response GO:0006954 9.88 NFKB1 NCR3 IL6 IL10 CXCR3 CCL5
3 cellular response to lipopolysaccharide GO:0071222 9.81 NFKB1 KLRK1 IL6 IL10
4 response to virus GO:0009615 9.77 IFNG FOXP3 CCL5
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.73 IL6 IL2 IFNG CCL5
6 negative regulation of T cell proliferation GO:0042130 9.67 IL2RA IL10 FOXP3
7 positive regulation of T cell proliferation GO:0042102 9.67 IL6 IL2RA IL2 CCL5
8 negative regulation of inflammatory response GO:0050728 9.65 NFKB1 IL2RA IL2 IL10 FOXP3
9 natural killer cell activation GO:0030101 9.63 NCR3 KLRK1 IL2
10 positive regulation of T cell differentiation GO:0045582 9.61 IL2RA IL2
11 positive regulation of natural killer cell mediated cytotoxicity GO:0045954 9.6 NCR3 KLRK1
12 negative regulation of immune response GO:0050777 9.58 IL2RA FOXP3
13 positive regulation of regulatory T cell differentiation GO:0045591 9.58 IL2 FOXP3
14 positive regulation of immunoglobulin secretion GO:0051024 9.57 IL6 IL2
15 negative regulation of interleukin-17 production GO:0032700 9.56 IFNG FOXP3
16 interleukin-2-mediated signaling pathway GO:0038110 9.55 IL2RA IL2
17 negative regulation of T-helper 17 cell differentiation GO:2000320 9.52 IL2 FOXP3
18 negative regulation of lymphocyte proliferation GO:0050672 9.5 IL2RA IL2 FOXP3
19 cytokine-mediated signaling pathway GO:0019221 9.5 MMP9 IL6 IL2RA IL2 IL10 IFNL3
20 regulation of T cell homeostatic proliferation GO:0046013 9.48 IL2RA IL2
21 regulation of regulatory T cell differentiation GO:0045589 9.46 IL2RA IL2 IFNG FOXP3
22 immune response GO:0006955 9.28 NCR3 KIR2DL3 IL6 IL2RA IL2 IL10

Molecular functions related to Tropical Spastic Paraparesis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.1 IL6 IL2 IL10 IFNL3 IFNG CCL5

Sources for Tropical Spastic Paraparesis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....